Expertise PartnerOcunexus is developing upstream, differentiated technology modulating the inflammasome. Ocunexus technology inhibits pathological overexpression of Connexin43 (Cx43) hemichannel, a nidus for the assembly of NLRP3. The company has a Phase 2 ready orally administered Cx43 inhibitor for IND filing Q4. Disease targets are “Dry Form” of Macular Degeneration (AMD) representing 85% of all AMD, with no approved treatment, and Diabetic Retinopathy where current therapy fails >50% of the time. Both are leading causes of blindness.
BPS focuses in the design, expression, purification, and characterization of active recombinant enzymes and enzyme complexes. We are also skilled in developing recombinant cell lines and all aspects of biochemical and cell-based assay development. As a primary manufacturer, BPS can supply products in large-scale bulk quantities and welcomes inquiries for contract and custom manufacturing within a variety of research areas.
ZyVersa is a clinical stage company developing first-in-class drugs for inflammatory and renal diseases. Development includes a novel inflammasome inhibitor, IC 100, and a cholesterol efflux mediator for FSGS, an orphan renal disease.
IC 100 is a mAb that uniquely inhibits the ASC component of multiple inflammasomes. As numerous inflammatory diseases are associated with activation of more than one inflammasome, IC 100 is expected to have a therapeutic effect in a broad group of disorders.